ocrelizumab
Drug Details
- Generic Name
- ocrelizumab
- Brand Names
- OCREVUS
- Application Number
- BLA761053
- Sponsor
- Lonza Biologics, Inc.
- NDC Codes
- 3
- Dosage Forms
- LIQUID, INJECTION
- Routes
- INTRAVENOUS
- Active Ingredients
- OCRELIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE OCREVUS ZUNOVO is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults OCREVUS ZUNOVO is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 )